Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Organovo Holdings Inc    

ORGANOVO HOLDINGS INC

  Report  
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 3,20 M
EBIT 2019 -27,4 M
Net income 2019 -26,8 M
Finance 2019 33,0 M
Yield 2019 -
Sales 2020 3,35 M
EBIT 2020 -32,0 M
Net income 2020 -31,6 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 26,6x
Capi. / Sales2020 35,2x
Capitalization 118 M
More Financials
Company
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused... 
More about the company
Surperformance© ratings of Organovo Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ORGANOVO HOLDINGS INC
05/17ORGANOVO : Announces Release Date for Preliminary Fiscal Fourth-Quarter 2019 Fin..
AQ
04/17Organovo to Present at 2019 Cell & Gene Meeting on the Mediterranean
GL
03/14ORGANOVO : to Participate in Nash Panel Discussion at 31st Annual Roth Conferenc..
AQ
02/20ORGANOVO HOLDINGS, INC. : Change in Directors or Principal Officers, Financial S..
AQ
02/20Organovo Appoints New Board Member
GL
02/07ORGANOVO : Fiscal 3Q Earnings Snapshot
AQ
02/07ORGANOVO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/07ORGANOVO HOLDINGS, INC. : Results of Operations and Financial Condition, Financi..
AQ
02/07Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Third..
GL
01/17Organovo Announces Release Date for Fiscal Third-Quarter 2019 Financial Resul..
GL
More news
Analyst Recommendations on ORGANOVO HOLDINGS INC
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
More sector news : Biotechnology & Medical Research - NEC
Chart ORGANOVO HOLDINGS INC
Duration : Period :
Organovo Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,83 $
Spread / Average Target 187%
EPS Revisions
Managers
NameTitle
Taylor J. Crouch President, Chief Executive Officer & Director
Kirk D. Malloy Chairman
Craig S. Kussman Chief Financial Officer
Steven G. Hughes Chief Medical Officer
James T. Glover Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ORGANOVO HOLDINGS INC118
IQVIA HOLDINGS INC15.06%26 365
LONZA GROUP24.54%23 366
CELLTRION, INC.--.--%21 024
INCYTE CORPORATION21.40%16 555
EXACT SCIENCES CORPORATION52.44%12 422